CUE Cue Biopharma Inc

Cue Biopharma to Host Business Update Call and Webcast

Cue Biopharma to Host Business Update Call and Webcast

CAMBRIDGE, Mass., May 10, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patient’s body, announced today it will host a conference call and webcast to provide a business update on Monday, May 17, 2021 at 4:30 p.m. EDT. Live and archived versions of the event can be accessed via the Company’s .

Members of the Cue Biopharma executive management team will provide a clinical update from the Company’s ongoing Phase 1a/1b monotherapy dose escalation clinical trial of CUE-101, including discussing the confirmed partial response (PR) recently reported in one patient receiving CUE-101 as second-line treatment for HPV+ recurrent/metastatic head and neck squamous cell carcinoma. Management will also provide an update on the Company’s most recent technology platform developments and pipeline progress as well as updates on its strategic objectives and anticipated milestones.

Webcast Details

Monday, May 17, 2021 at 4:30 p.m. EDT

Investors: 855-327-6837

International: 631-891-4304

Conference ID: 10014734

Webcast:

About Cue Biopharma

Cue Biopharma, a clinical-stage biopharmaceutical company, is engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells directly within the patient’s body to transform the treatment of cancer, infectious disease and autoimmune disease. The company’s proprietary platform, Immuno-STAT™ (Selective Targeting and Alteration of T cells) is designed to harness the body’s intrinsic immune system without the need for ex vivo manipulation.

Headquartered in Cambridge, Massachusetts, we are led by an experienced management team and independent Board of Directors with deep expertise in immunology and immuno-oncology as well as the design and clinical development of protein biologics.



For more information, visit  and follow us on Twitter at .

Investor Contact

George B. Zavoico, Ph.D.

VP, Investor Relations & Corporate Development

Cue Biopharma, Inc.

Media Contact

Darren Opland, Ph.D.

LifeSci Communications



EN
10/05/2021

Underlying

CUECue Biopharma Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Cue Biopharma Inc

 PRESS RELEASE
Free
CUE Cue Biopharma I...

Cue Biopharma Announces Preclinical Safety and Tolerability Data for C...

Cue Biopharma Announces Preclinical Safety and Tolerability Data for CUE-401 for the Treatment of Autoimmune and Inflammatory Diseases In two non-GLP studies, CUE-401 was well tolerated with no adverse events observed Proof-of-concept studies reinforce promising preclinical profile and therapeutic potential of CUE-401 BOSTON, Mass., Feb. 17, 2026 (GLOBE NEWSWIRE) --  (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of autoimmune and inflammatory disea...

February 17, 2026 1 EN
 PRESS RELEASE
Free
CUE Cue Biopharma I...

Cue Biopharma Appoints Industry Veteran Lucinda Warren as Chief Financ...

Cue Biopharma Appoints Industry Veteran Lucinda Warren as Chief Financial and Business Officer BOSTON, Feb. 12, 2026 (GLOBE NEWSWIRE) --  (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of autoimmune and inflammatory diseases, today announced that Lucinda Warren, who has served as Cue Biopharma’s chief business officer (CBO) since September 2024, has been appointed chief financial and business officer (CFBO) effective February 9, 2026. “The combination...

February 12, 2026 1 EN
Free Trial
CUE Cue Biopharma I...

Cue Biopharma Inc: 1 director

A director at Cue Biopharma Inc maiden bought 323,857 shares at 0.308USD and the significance rating of the trade was 59/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two ye...

CUE CUE BIOPHARMA INC
01/02/26 January 2, 2026 1 EN
 PRESS RELEASE
Free
CUE Cue Biopharma I...

Cue Biopharma Announces Pricing of $10 Million Public Offering

Cue Biopharma Announces Pricing of $10 Million Public Offering BOSTON, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of autoimmune disease, today announced the pricing of an underwritten public offering of 35,714,286 shares of its common stock (or pre-funded warrants to purchase shares of common stock in lieu thereof) and accompanying common stock warrants to purchase an aggregate of 17,857,143 sha...

December 19, 2025 1 EN
 PRESS RELEASE
Free
CUE Cue Biopharma I...

Cue Biopharma Announces Proposed Public Offering

Cue Biopharma Announces Proposed Public Offering BOSTON, Dec. 18, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of autoimmune disease, today announced that it is commencing an underwritten public offering of shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and accompanying warrants to purchase shares of common stock. In addition, Cue Biopharma intends to grant the underwriters an op...

December 18, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch